Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.

Edgewise Therapeutics Stock Performance

Edgewise Therapeutics stock opened at $25.01 on Tuesday. The stock’s 50 day moving average price is $27.44 and its 200 day moving average price is $27.42. The firm has a market capitalization of $2.37 billion, a PE ratio of -16.67 and a beta of 0.20. Edgewise Therapeutics has a one year low of $14.90 and a one year high of $38.12.

Wall Street Analysts Forecast Growth

EWTX has been the topic of several recent research reports. Wedbush boosted their price target on Edgewise Therapeutics from $44.00 to $45.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Evercore ISI lifted their price objective on Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Truist Financial lifted their price objective on Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, November 27th. Finally, Stifel Nicolaus assumed coverage on Edgewise Therapeutics in a report on Wednesday, January 22nd. They set a “hold” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.29.

Insider Buying and Selling

In other Edgewise Therapeutics news, insider Alan J. Russell sold 1,200 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $30.13, for a total transaction of $36,156.00. Following the completion of the transaction, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. The trade was a 7.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin Koch sold 8,636 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $30.03, for a total value of $259,339.08. Following the transaction, the chief executive officer now owns 14,478 shares of the company’s stock, valued at $434,774.34. This trade represents a 37.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 164,545 shares of company stock worth $4,605,305 in the last three months. 24.11% of the stock is owned by insiders.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.